Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial

Jean-Michel Hannoun-Levi,Marie-Eve Chand-Fouche,Tanguy Pace-Loscos,Mathieu Gautier,Jocelyn Gal,Renaud Schiappa,Nina Pujol

Clinical and Translational Radiation Oncology（2022）

Cited 1|Views6

No score

Abstract

•LDR brachytherapy is a validated therapy for low-risk prostate cancer.•HDR brachytherapy aims to decrease urinary side effects.•A single fraction of 20 Gy HDR brachytherapy leads to sub-optimal biochemical control.•No Grade 3 urinary/digestive toxicity after a single fraction of HDR brachytherapy.•2 fractions of HDR brachytherapy constitute a promising approach.

Translated text

Key words

ADT,bRFS,CSS,CT,CTCAE,CTV,D90,DFS,DNR,DVH,EBRT,EQD2,GI,GTV1,GTV2,GU,HDB,HR,IR,IIEF,IPSS,ISUP,ITPL,LDR,LIR,LR,lRFS,MFU,mRFS,mpMRI,NCCN,OAR,OS,PC,PET,PSA,pts,PUF,PVRV,QLQC30,QLQ-PR25,QoL,SBRT,SDRT,TURP,V100,V150,V200,V85R,V110U

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined